Noxilizer Board of Directors

Lawrence Bruder, Noxilizer’s current CEO, brings over 25 years of leadership and operational experience in large and small life science companies, including Becton Dickinson, Applied Biosystems, Leica, Olympus, and Guava Technologies. Most recently, he was President and CEO of venture-backed Guava Technologies, which was sold to Millipore Biosciences in 2009. Much of his experience prior to Guava was at Becton Dickinson, where he held a number of significant positions over a 10-year period. His responsibilities in both companies included the clinical and regulatory aspects of 510(k) submittals to the FDA for medical devices, significant commercial interaction with pharmaceutical companies, and high-level business development transactional activity; all of these being a critical part of Noxilizer’s needs. Mr. Bruder holds a B.S. from Rochester Institute of Technology and Master of Management in Marketing and Economics from the Kellogg School of Management at Northwestern University.

Kyle J. Salyers is a Co-founder and Managing Director of CHV Capital, Inc. (An Indiana University Health Company). He previously served as an Innovation Fellow and Senior Investment Manager at Rose-Hulman Ventures. Mr. Salyers currently represents CHV on the boards of NeoChord, Celleration, NICO Corporation and MedVentive. His civic activities include service on the Board of Directors of Techpoint, the Indiana University School of Nursing National Advisory Board, the Advisory Board of the Eiteljorg Museum of Native American and Western Art, and the DePauw University 361 National Advisory Board. He has been recognized by the Indianapolis Business Journal as one of Central Indiana’s most influential technology leaders (2000), acknowledged as one of Central Indiana’s top business and community leaders under the age of 40 (2007), and identified by Junior Achievement as one of Indianapolis’ Best and Brightest Young Executives (2009). Mr. Salyers is a graduate of DePauw University with degrees in Economics and Sociology and was a four year varsity basketball player. He has an MBA from the University of Notre Dame.

Jerry Parrott has been Vice President, Corporate Communications and Public Policy of Human Genome Sciences, Inc. since July 1, 2001. As Principal of Policy Advocates, Inc., from 1995-2001, Mr. Parrott's clients included HGS, Bristol-Myers Squibb, Ciba-Geigy, Diversa, Genentech, HealthCare Ventures, Hoffmann-La Roche, Western Digital, Wyeth and other companies. He held senior policy and corporate communications management positions with Bristol-Myers Squibb Company from 1979 to 1995, American Hospital Supply Corporation from 1976 to 1979, and Walgreen Company from 1973 to 1976. Mr. Parrott has helped launch important therapeutic products in immunology, oncology, infectious disease and pain relief, and has helped bring two prescription products over the counter. He received his B.A. from the University of South Florida and attended graduate school as a University Fellow at Northwestern University. Mr. Parrott is Chair of the Board of Directors of Maryland Health Care Product Development Corporation, Senior Advisor to the Maryland Life Sciences Advisory Board, and a Director of the Tech Council of Maryland, MDBio and BioHealth Innovation.

Alfred R. Berkeley III, a Noxilizer individual investor since 2006, Mr. Berkeley has over 35 years of experience in the financial industry. He is currently the Vice Chairman of Gentag, Inc., a developer of technology for near field communications. Formerly, Berkeley Chaired the Board of Pipeline Financial Group, Inc, the parent of Pipeline Trading Systems, LLC, an equities and options trading company. Mr. Berkeley has served as President and then Vice-Chairman of The NASDAQ Stock Market, Inc. Before NASDAQ, he was a Managing Director of Alex Brown & Sons, a leading investment bank, and co-founded Alex Brown’s Technology Group in 1975. The Technology Group completed about 500 financial offerings for clients while he was associated with Alex Brown. Mr. Berkeley was a trustee of the Johns Hopkins University, served on the board of the Johns Hopkins University Applied Physics Laboratory, LLC. and is a Trustee of Allen University in Columbia, South Carolina. He is a Director of the World Economic Forum USA and was Chairman of XBRL US, a non-profit established to set standards for GAAP taxonomies to be used by public companies to report to the US Securities and Exchange Commission. He is a director of XBRL International. Mr. Berkeley is a graduate of the Wharton School of Finance of the University of Pennsylvania (MBA) and the University of Virginia (B.A.). He served as an officer in the United States Air Force.

John L. Brooks III is the President and CEO of the Joslin Diabetes Center. Joslin is the world’s leader in diabetes research, care, education and prevention. A well-known life sciences executive, Mr. Brooks has been a consultant to life science companies and was a co-founder of Prism Venture Partners, a venture capital firm which raised over $1.25 billion in capital. He was formerly a general manager at Pfizer/Valleylab in Boulder, Colo., where he developed and executed a minimally-invasive surgery and emerging businesses strategy. Prior to that, at Pfizer/Strato Medical, he led the growth of a rapidly evolving vascular access medical device business. Mr. Brooks has co-founded three life sciences companies including Insulet (PODD). He is a biotechnology advisory board member for Draper Labs and a member of M2D2, an early stage medical technology accelerator, and a board member of Suffolk University. He holds an M.S. in Business and a B.B.A. cum laude from the University of Massachusetts at Amherst. He is a Certified Public Accountant and a Certified Financial Planner.

Stephen Schaefer, J.D., is an intellectual property attorney and principal in the Minneapolis, MN office of Fish & Richardson, which he joined in 1995. He received his law degree from the University of Minnesota (1992) and also has degrees in electrical engineering and engineering management. Mr. Schaefer served as a judicial law clerk to Judge Alvin A. Schall of the Federal Circuit Court of Appeals in Washington, DC (1993-95), was an attorney at Pennie & Edmonds in New York City (1992-93), and served as an officer in the United States Air Force (1985-89). His expertise includes patent portfolio strategy and development; intellectual property agreements; and managing patent infringement litigation with the benefit of having worked as a full-time litigator early in his legal career. Mr. Schaefer was lead outside intellectual property counsel to Boston Scientific Corporation in connection with its $27B acquisition of Guidant Corporation, in 2005-06. He also advises several venture fund clients in connection with their investment decisions, and has conducted over 30 intellectual property due diligence studies over the years for those clients.

Lars Hanan is Co-founder and Managing Partner at BroadOak Capital Partners LLC. With 20 years of corporate finance and mergers and acquisitions experience, Mr. Hanan has executed over a hundred transactions in a broad range of industries. Prior to BroadOak, he built and managed the life sciences advisory business at Mercator Capital. Before joining Mercator, he held senior positions in mergers and acquisitions at ABN AMRO Investment Banking, SG Cowen, Kidder, Peabody and Lehman Brothers. He currently serves on the boards of Marligen Biosciences, A&G Pharmaceuticals and Noxilizer, Inc. Mr. Hanan holds a B.A. in Economics from the University of Virginia and an MBA from the Kellogg School of Management at Northwestern University.